Windlas Biotech misses Plant 6 timeline as regulatory hit cuts revenue
Regulatory action wiped out the company's codeine syrup business, while geopolitical tension and solvent costs weigh on margins.
— 3 earlier stories on Windlas Biotech Ltd. →What's new with Windlas Biotech Ltd.
- Plant 6 commercialization is pushed to H1 FY27 despite mechanical completion.
- The codeine syrup business loss creates a ₹50-60 cr revenue hole.
- Exports grew 40% annually to ₹46 cr, with Q4 growth hitting 67%.
Why this matters for Windlas Biotech Ltd.
The delay at Plant 6, paired with the loss of a major product line, forces the company to find new revenue sources while fighting margin decay. Rising API costs leave little room for error as the firm works to replace its lost liquid product portfolio.
What we're watching
- The speed of replacement for the lost syrup revenue.
- Margin recovery against the current cost-inflationary trend.
- The start date for commercial production at Plant 6.
The full read
Windlas Biotech faces two distinct headwinds. First, the regulatory loss of its codeine syrup business removed ₹50-60 crore in annual revenue, leaving the firm to source liquid product alternatives. Second, the Plant 6 expansion will not see commercial production until the first half of the next financial year, missing earlier expectations. Margin pressure is also rising as the firm pays more for solvents and API supplies hit by West Asia geopolitical tension. Exports provided some relief with 40% annual growth to ₹46 crore, aided by a 67% jump in the final quarter. Management sees a theoretical revenue ceiling of ₹1,000 crore and 10-15% efficiency upside, but the immediate test is filling the revenue gap while navigating a tightening cost environment.